Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-Myositis: CABA-201 in Active Idiopathic Inflammatory Myopathy
NCT06154252Phase 3Recruiting
- Sponsor
- Cabaletta Bio
- Start
- Dec 2023
- Primary completion
- Jul 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 4
01
Overview
A Phase 3 trial of resecabtagene autoleucel in idiopathic inflammatory myopathy (IIM), dermatomyositis (DM), antisynthetase syndrome (ASSD), immune-mediated necrotizing myopathy (IMNM), juvenile idiopathic inflammatory myopathy (JIIM), sponsored by Cabaletta Bio. Started Dec 2023; status: recruiting.
02
Drugs
resecabtagene autoleucel
03
Conditions
idiopathic inflammatory myopathy (IIM)dermatomyositis (DM)antisynthetase syndrome (ASSD)immune-mediated necrotizing myopathy (IMNM)juvenile idiopathic inflammatory myopathy (JIIM)
Beyond the preview
Go deeper on NCT06154252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06154252.